Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 32 Colonic Neoplasms 8 Rectal Neoplasms 7 Neoplasm Metastasis 5 Stomach Neoplasms 3 Pancreatic Neoplasms 3 Gallbladder Neoplasms 3 Cholangiocarcinoma 3 Neutropenia 2 Bile Duct Neoplasms 2 Adenocarcinoma 2 mCRC 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Microsatellite-stable Colorectal Cancer 1 Lung Neoplasms 1 High-grade Extra Pulmonary Neuroendocrine Cancer 1 Gastric Cancer Adenocarcinoma Metastatic 1 First-line Treatment 1 Esophageal Squamous Cell Carcinoma 1 EFS 1 Dihydropyrimidine Dehydrogenase Deficiency 1 Clinical Stage III Gastric Cancer AJCC v8 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Trastuzumab 304 Paclitaxel 257 Cyclophosphamide 251 Docetaxel 238 Capecitabine 175 Letrozole 163 Carboplatin 163 Fulvestrant 145 Doxorubicin 145 Bevacizumab 121 Anastrozole 106 Tamoxifen 102 exemestane 94 Vinorelbine 91 Epirubicin 90 pertuzumab 89 Gemcitabine 84 Lapatinib 80 Albumin-Bound Paclitaxel 74 Radiotherapy 71 pembrolizumab 70 palbociclib 64 130-nm albumin-bound paclitaxel 58 eribulin 56 Cisplatin 55 Everolimus 49 pyrotinib 45 Taxes 44 Goserelin 43 Neoadjuvant Therapy 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × trifluridine tipiracil drug combination × Clear all

NCT04489173 2026-05-22

TIBET

Borstkanker Onderzoek Groep

Phase 2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡